Single-Use Bioreactors Market Size, Share, Opportunities, And Trends By Product Type (Single Use Bioreactor Systems, Media Bags, Filtration Assemblies, Other Products), By Cell Type (Mammalian Cell, Bacteria, Yeast, Other Cell Types), By Molecule Type (Monoclonal Antibodies, Vaccines, Stem Cells, Gene-modified Cells, Other Molecule Types), By End-User (Pharmaceutical And Biopharmaceutical Industries, Contract Research Organisations, Other End Users), And By Geography - Forecasts From 2025 To 2030

The single-use bioreactors market is expected to grow at a CAGR of 14.55%, reaching a market size of US$7.258 billion in 2030 from US$5.462 billion in 2025.

A solitary-use bioreactor or single-use bioreactor is a bioreactor with an expendable pack rather than a culture vessel. Regularly, this alludes to a bioreactor in which the fixing in touch with the cell culture will be plastic, and this coating is encased inside a more long-lasting construction, so it is high in demand and more eco-friendly. The expanding pattern toward multi-drug offices demands the creation of various drugs utilizing a similar office, which further raises the demand for single-use bioreactors because of their adaptability in the development of different drugs without compromising the quality of drugs. Increasing research activities and developments in the field of biopharmaceutics are giving potential to the market growth of single-use bioreactors.

The flexibility showcased by single-use bioreactors in producing multiple drugs without compromising quality is driving their market value in the medical and biopharmaceutical fields. The reduction in automation complexity offered by single-use bioreactors is also expected to increase the demand for them among large companies and industries.

The policies offered by the governments of several countries in support of research and development in the pharmaceutical and biotechnological fields are also positively influencing the global single-use bioreactors market growth. The efficiency offered by single-use bioreactors by reducing the costly and time-consuming cleaning process is expected to bolster their demand during the forecast period.

Market Drivers:

• Rise in biopharmaceutical research and development is expected to drive the single-use bioreactors market

The interest in biopharmaceuticals is expanding worldwide because of the growing geriatric population percentage, as this population is more susceptible to a wide scope of infections. Looking at the increasing opportunities, worldwide organizations, and major companies are investing more in biopharmaceutical research and development programs. When compared to other assembling ventures, the biopharmaceutical industry contributes many times more in terms of research and development.  According to the reports of the FIP (International Pharmaceutical Federation) in 2018, the world’s biopharmaceutical organizations had collectively invested about 102 billion USD in research and development programs.

Single-use bioreactors are vital to the biopharmaceutical component-producing work processes. They make up an enormous amount of small and mid-scale biopharmaceutical manufacturing, especially in clinical testing and innovative work. Because of their benefits over traditional biomanufacturing strategies, their popularity has expanded in biopharmaceutical research and development. The increasing research and development programs are considered a positive sign for the single-use bioreactor market’s growth.

• The flexibility offered by single-use bioreactors would significantly increase the demand for single-use bioreactors.

The flexibility offered by single-use bioreactors is another major factor positively driving the single-use bioreactor market’s growth. The efficiency showcased by these bioreactors in manufacturing different types of drugs and assisting different biopharmaceutical processes is increasing the application of single-use bioreactors in various fields. The large investments of major companies in developing single-use bioreactors compared to conventional ones are significantly boosting the global single-use bioreactor market growth. 

Single-use bioreactors are increasingly popular due to their adaptability to various scales, reduced turnaround time, cost-effectiveness, and minimization of cross-contamination risks. They are suitable for a wide range of applications, from laboratory-scale research to large-scale industrial production. The setup and cleaning processes are faster than traditional stainless-steel bioreactors, allowing for more efficient production cycles.

Additionally, single-use bioreactors eliminate the need for significant infrastructure and cleaning validation costs, making them an economical choice. This is particularly important in the production of biopharmaceuticals and other sensitive products, where maintaining product purity is crucial.

The North American region is predicted to hold a significant market share in the future.

North America is the market leader. Geographically, the North American region is estimated to hold the lion's share of the single-use bioreactor market. The presence of well-established medical and pharmaceutical infrastructure in the North American countries and the presence of major players are some of the prominent reasons behind the region's large market share in the single-use bioreactor market.

North America, particularly the United States, is a global leader in the biopharmaceutical industry, with numerous biotech and pharmaceutical companies using bioreactors for production. The demand for single-use bioreactors, offering flexibility and cost-efficiency, is on the rise due to their advantages such as reduced contamination risk, faster turnaround times, and lower capital investment. The growth of biotechnology startups in the region has also driven the adoption of single-use bioreactors, making them an attractive choice for bioprocess development and manufacturing.

Strategic collaborations between key players in the biopharmaceutical industry and single-use bioreactor manufacturers contribute to market growth. Regulatory agencies in North America have recognized the advantages of single-use bioreactors and provided support for their use in biopharmaceutical manufacturing. Technological advancements in single-use bioreactor technology, such as sensor integration, control systems, and disposable materials, contribute to their broader acceptance. The North American region's strong presence in the global biopharmaceutical market contributes to its competitiveness in the single-use bioreactors marketplace.

Key Developments:

• October 2024: Lonza acquired Genentech biologics manufacturing site in Vacaville, California, from Roche for $1.2 billion. The site has about 330,000 liters of bioreactor capacity and gives Lonza a significant boost to its U.S. manufacturing. The site adds approximately 750 workers to Lonza's rolls and is taken into its mammalian manufacturing unit. Upgrading the facility to the tune of CHF 500 million as planned, Lonza would ensure it met the rising demand for next-generation biologics therapies.
• September 2024: MilliporeSigma has launched the Mobius ADC Reactor, the first commercially available stainless steel or glass reactor designed to scale up for manufacturing antibody-drug conjugates (ADCs). The new reactor addresses the unique challenges associated with ADC production by allowing for fast turnaround times and reducing the potential for cross-contamination compared to stainless steel or glass reactors. It can increase efficiency by 70% and reduce waste; this advance is possible owing to the Ultimus Film technology used. This launch forms part of MilliporeSigma's efforts to speed up the development of critical therapies for patients worldwide.

 

• June 2024: AGC Biologics expanded its site in Copenhagen, doubling the company's single-use bioreactor capacity for mammalian cell culture. The new building offers an additional capacity to produce 150 drug product batches each year. There are eight 2,000-liter bioreactors, and in general, this expands the site's capabilities very significantly. The expansion comprises 19,000 square meters with advanced manufacturing and quality control labs. AGC Biologics invested around $200 million in this project which is already operational with its first clinical product.

Single-Use Bioreactors Market Scope:

Report Metric	Details
Market Size Value in 2025	US$5.462 billion
Market Size Value in 2030	US$7.258 billion
Growth Rate	CAGR of 14.55%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segments Covered	Product Type Cell Type Molecule Type End-User Geography
Companies Covered	ABEC Inc. Celltainer Distek Inc. Eppendorf AG GE Healthcare
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

 

Key Market Segmentation:

• By Product Type
  • Single-Use Bioreactor Systems
  • Media Bags
  • Filtration Assemblies
  • Other Products
• By Cell Type
  • Mammalian cell
  • Bacteria
  • Yeast
  • Other Cell Types
• By Molecule Type
  • Monoclonal Antibodies
  • Vaccines
  • Stem Cells
  • Gene-modified Cells
  • Other Molecule Types
• By End-User
  • Pharmaceutical and Biopharmaceutical industries
  • Contract Research Organisations
  • Other End-Users
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • UK
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. SINGLE-USE BIOREACTORS MARKET BY PRODUCT TYPE

5.1. Introduction

5.2. Single-Use Bioreactor Systems

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Media Bags

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

5.4. Filtration Assemblies

5.4.1. Market Opportunities and Trends

5.4.2. Growth Prospects

5.4.3. Geographic Lucrativeness

5.5. Other Products

5.5.1. Market Opportunities and Trends

5.5.2. Growth Prospects

5.5.3. Geographic Lucrativeness

6. SINGLE-USE BIOREACTORS MARKET BY CELL TYPE

6.1. Introduction

6.2. Mammalian cell

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Bacteria

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Yeast

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

6.5. Other Cell Types

6.5.1. Market Opportunities and Trends

6.5.2. Growth Prospects

6.5.3. Geographic Lucrativeness

7. SINGLE-USE BIOREACTORS MARKET BY MOLECULE TYPE

7.1. Introduction

7.2. Monoclonal Antibodies

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Vaccines

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

7.4. Stem Cells

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

7.4.3. Geographic Lucrativeness

7.5. Gene-modified Cells

7.5.1. Market Opportunities and Trends

7.5.2. Growth Prospects

7.5.3. Geographic Lucrativeness

7.6. Other Molecule Types

7.6.1. Market Opportunities and Trends

7.6.2. Growth Prospects

7.6.3. Geographic Lucrativeness

8. SINGLE-USE BIOREACTORS MARKET BY END-USER

8.1. Introduction

8.2. Pharmaceutical and Biopharmaceutical industries

8.2.1. Market Opportunities and Trends

8.2.2. Growth Prospects

8.2.3. Geographic Lucrativeness

8.3. Contract Research Organisations

8.3.1. Market Opportunities and Trends

8.3.2. Growth Prospects

8.3.3. Geographic Lucrativeness

8.4. Other End-Users

8.4.1. Market Opportunities and Trends

8.4.2. Growth Prospects

8.4.3. Geographic Lucrativeness

9. SINGLE-USE BIOREACTORS MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Product Type

9.2.2. By Cell Type

9.2.3. By Molecule Type 

9.2.4. By End-User

9.2.5. By Country

9.2.5.1. USA

9.2.5.1.1. Market Opportunities and Trends

9.2.5.1.2. Growth Prospects

9.2.5.2. Canada

9.2.5.2.1. Market Opportunities and Trends

9.2.5.2.2. Growth Prospects

9.2.5.3. Mexico

9.2.5.3.1. Market Opportunities and Trends

9.2.5.3.2. Growth Prospects

9.3. South America

9.3.1. By Product Type

9.3.2. By Cell Type

9.3.3. By Molecule Type 

9.3.4. By End-User

9.3.5. By Country 

9.3.5.1. Brazil

9.3.5.1.1. Market Opportunities and Trends

9.3.5.1.2. Growth Prospects

9.3.5.2. Argentina

9.3.5.2.1. Market Opportunities and Trends

9.3.5.2.2. Growth Prospects

9.3.5.3. Others

9.3.5.3.1. Market Opportunities and Trends

9.3.5.3.2. Growth Prospects

9.4. Europe

9.4.1. By Product Type

9.4.2. By Cell Type

9.4.3. By Molecule Type 

9.4.4. By End-User

9.4.5. By Country

9.4.5.1. Germany

9.4.5.1.1. Market Opportunities and Trends

9.4.5.1.2. Growth Prospects

9.4.5.2. France

9.4.5.2.1. Market Opportunities and Trends

9.4.5.2.2. Growth Prospects

9.4.5.3. UK

9.4.5.3.1. Market Opportunities and Trends

9.4.5.3.2. Growth Prospects

9.4.5.4. Others

9.4.5.4.1. Market Opportunities and Trends

9.4.5.4.2. Growth Prospects

9.5. Middle East and Africa

9.5.1. By Product Type

9.5.2. By Cell Type

9.5.3. By Molecule Type 

9.5.4. By End-User

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.1.1. Market Opportunities and Trends

9.5.5.1.2. Growth Prospects

9.5.5.2. UAE

9.5.5.2.1. Market Opportunities and Trends

9.5.5.2.2. Growth Prospects

9.5.5.3. Others

9.5.5.3.1. Market Opportunities and Trends

9.5.5.3.2. Growth Prospects

9.6. Asia Pacific

9.6.1. By Product Type

9.6.2. By Cell Type

9.6.3. By Molecule Type 

9.6.4. By End-User

9.6.5. By Country

9.6.5.1. China

9.6.5.1.1. Market Opportunities and Trends

9.6.5.1.2. Growth Prospects

9.6.5.2. India

9.6.5.2.1. Market Opportunities and Trends

9.6.5.2.2. Growth Prospects

9.6.5.3. Japan

9.6.5.3.1. Market Opportunities and Trends

9.6.5.3.2. Growth Prospects

9.6.5.4. South Korea

9.6.5.4.1. Market Opportunities and Trends

9.6.5.4.2. Growth Prospects

9.6.5.5. Taiwan

9.6.5.5.1. Market Opportunities and Trends

9.6.5.5.2. Growth Prospects

9.6.5.6. Thailand

9.6.5.6.1. Market Opportunities and Trends

9.6.5.6.2. Growth Prospects

9.6.5.7. Indonesia

9.6.5.7.1. Market Opportunities and Trends

9.6.5.7.2. Growth Prospects

9.6.5.8. Others

9.6.5.8.1. Market Opportunities and Trends

9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. ABEC Inc.

11.2. Celltainer

11.3. Distek Inc.

11.4. Eppendorf AG

11.5. GE Healthcare

11.6. Thermo Fisher Scientific

11.7. Parker Hannifin

11.8. Danaher

11.9. PBS Biotech 

11.10. Cellexus 

11.11. Applikon Biotechnology

ABEC Inc.

Celltainer

Distek Inc.

Eppendorf AG

GE Healthcare

Thermo Fisher Scientific

Parker Hannifin

Danaher

PBS Biotech 

Cellexus 

Applikon Biotechnology